Arthritis Research & Therapy最新文献

{"title":"Clinical and immunological biomarkers can identify proliferative changes and predict renal flares in lupus nephritis","authors":"Marta Calatroni, Emanuele Conte, Matteo Stella, Federica De Liso, Francesco Reggiani, Gabriella Moroni","doi":"10.1186/s13075-025-03536-5","DOIUrl":"https://doi.org/10.1186/s13075-025-03536-5","url":null,"abstract":"Kidney involvement is frequent in SLE, with proliferative lupus nephritis (LN) forms and nephritic flares being key predictors of poor outcomes. Conflicting results have been reported for anti-C1q antibodies among the serological markers. Our purpose was to assess the value of immunological tests (C3,C4 complement fractions, anti-DNA and antiC1q antibodies) in predicting histological classes and flares of lupus nephritis (LN). For histological class prediction, we evaluated the immunological tests performed on the day of kidney biopsy by linear and multiple regression analyses. For flare prediction, univariable and multivariable Cox analyses were made at baseline, 6, and 12 months. Of 61 participants in the study, 47 had proliferative (III, IV) and 14 non-proliferative LN (II, V) at kidney biopsy. In proliferative LN, anti-DNA (p = 0.0186) and anti-C1q antibodies (Ab) (p = 0.0050) were significantly higher, and serum C3 and C4 lower (p = 0.0026; p = 0.0212) compared to non-proliferative LN. At multiple regression analysis, the best association to differentiate proliferative from non-proliferative LN was the number of urinary erythrocytes (OR 3.2292; CI 1.2585–8.2858; p = 0.0148) and anti-C1qAb (OR 1.0288; CI 1.0016–1.0568; p = 0.0380). Of 53 patients evaluated for flare predictions, followed for 60.69 (37.20-78.704) months, 10 (18.86%) had a renal flare at 28.19 months (24.84–39.38, range:16.3–55.8) from therapy initiation. At univariable analysis, anti-C1qAb (p = 0.0340, p = 0.0005) and no-use hydroxychloroquine (p = 0.0313, p = 0.0276) predicted flares at baseline and six months. Anti-C1qAb (p = 0.0047), non-use hydroxychloroquine (p = 0.0252), anti-C1qAb ≥ 40UA (p = 0.0047), 24/h proteinuria (p = 0.0185), and proteinuria ≥ 0.5 g/day (p = 0.0216) predicted flares at 12 months. At multivariable analysis, anti-C1q > 40UA (OR 9.0721; CI 0.9146–42.9882; p = 0.0057) and non-use of hydroxychloroquine (OR 0.1742 CI 0.0445–0.6823; p = 0.0126) were the independent predictors of renal flares. Immunological tests can differentiate proliferative from non-proliferative LN, but anti-C1qAb and urinary erythrocytes had the best predictive power. Only persistent high anti-C1qAb at 1 year and non-use of hydroxychloroquine seem to predict renal flares.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"102 4 Pt 1 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143736634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latent class analysis identifies distinct pain phenotypes in newly diagnosed systemic juvenile idiopathic arthritis","authors":"Hui Zhang, Xiaoqiong Wei, Wei Liu, Hongyao Leng, Qiao Shen, Xin Wan, Ximing Xu, Xianlan Zheng","doi":"10.1186/s13075-025-03534-7","DOIUrl":"https://doi.org/10.1186/s13075-025-03534-7","url":null,"abstract":"Patients with systemic juvenile idiopathic arthritis (sJIA) exhibit highly heterogeneous pain manifestations, which significantly impact their quality of life and disease prognosis. An understanding of the pain phenotypes for this disorder and their influencing factors is crucial for individualized pain management. To explore the pain phenotypes of newly diagnosed sJIA patients via latent class analysis (LCA), analyse the influencing factors of these phenotypes, and evaluate the impacts of different pain phenotypes on short-term inpatient outcomes. A retrospective cohort study was conducted by collecting the electronic health records of 165 patients who were first diagnosed with sJIA at the Children’s Hospital of Chongqing Medical University from January 2018 to July 2024. Patient pain characteristics, laboratory indicators, and inpatient outcome data were extracted. LCA was used to identify pain phenotypes, and multivariate logistic regression was used to analyse the influencing factors. The Lanza–Tan–Bray method and the data combination analysis technique were applied to evaluate the relationships between pain phenotypes and clinical outcomes. LCA categorized the pain phenotypes of sJIA patients into three distinct classes, including (1) Class 1: inflammation-related moderate to severe pain with functional impairment (53.9% of patients); (2) Class 2: mild intermittent pain with extra-articular symptoms (19.4% of patients); and (3) Class 3: no joint pain with mild functional impairment (26.7% of patients). The analysis revealed that age (P = 0.023) and serum IL-10 levels (P = 0.047) were significant factors influencing pain phenotypes. Significant differences were observed among different pain phenotypes in terms of hospital stay duration, intrahospital department transfer rates, and pain status at discharge. Pain in sJIA patients can be classified into three distinct phenotypes, which are influenced by factors such as age and IL-10 levels. The identification of these pain phenotypes has important clinical significance for developing individualized pain management strategies.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"13 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143736792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum phospholipids and sphingolipids are linked to early-stage osteoarthritis by lipidomic profiling","authors":"Gerrit Eichner, Gerhard Liebisch, Christiane Hild, Markus Rickert, Juergen Steinmeyer","doi":"10.1186/s13075-025-03537-4","DOIUrl":"https://doi.org/10.1186/s13075-025-03537-4","url":null,"abstract":"Osteoarthritis (OA) is associated with abnormal lipid metabolism, wherein elevated levels of phospholipids (PLs) and sphingolipids (SLs) in human and canine synovial fluid (SF) have been observed. The aim of this lipidomic study was to evaluate how closely blood lipid levels reflect changes in SF, building on previous findings. Lipids were extracted from knee SF and serum of 44 joint-healthy donors and 58 early (eOA) or late OA (lOA) patients. By electrospray ionization tandem mass spectrometry (ESI-MS/MS), we quantified the extracted lipids and conducted comprehensive statistical analyses. Human SF and serum had similar PL and SL compositions. Quantifying 91 lipid species from 6 major classes revealed OA-related changes in serum, with the lowest levels in healthy controls and elevated levels already in the eOA cohort. Generally, serum PL and SL levels were 3–12 times higher than in SF. Specific PL species were elevated in both SF and serum of eOA and lOA patients compared to healthy controls, while nearly 10% of the PL species measured were higher exclusively in the serum of OA patients. The significant lipidomic alterations that were detected at an average Outerbridge score of less than 2 suggest that certain serum PLs may serve as indicators for monitoring the early stages of OA even before radiologic detection is possible. With 10% of PL species elevated only in OA serum, our data implicate the existence of a systemic response that parallels the local lipid metabolic response to OA.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"36 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143736794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using in vivo calcium imaging to examine joint neuron spontaneous activity and home cage analysis to monitor activity changes in mouse models of arthritis","authors":"George L. Goodwin, Alina-Cristina Marin, Julia Vlachaki Walker, Carl Hobbs, Franziska Denk","doi":"10.1186/s13075-025-03515-w","DOIUrl":"https://doi.org/10.1186/s13075-025-03515-w","url":null,"abstract":"Studying pain in rodent models of arthritis is challenging. For example, assessing functional changes in joint neurons is challenging due to their relative scarcity amongst all sensory neurons. Additionally, studying pain behaviors in rodent models of arthritis poses its own set of difficulties. Commonly used tests, such as static weight-bearing, often require restraint, which can induce stress and consequently alter nociception. The aim of this study was to evaluate two emerging techniques for investigating joint pain in mouse models of rheumatoid- and osteo-arthritis: In vivo calcium imaging to monitor joint afferent activity and group-housed home cage monitoring to assess pain-like behaviors. Specifically, we examined whether there was increased spontaneous activity in joint afferents and reduced locomotor activity following induction of arthritis. Antigen induced arthritis (AIA) was used to model rheumatoid arthritis and partial medial meniscectomy (PMX) was used to model osteoarthritis. Group-housed home cage monitoring was used to assess locomotor behavior in all mice, and weight bearing was assessed in PMX mice. In vivo calcium imaging with GCaMP6s was used to monitor spontaneous activity in L4 ganglion joint neurons retrogradely labelled with fast blue 2 days following AIA and 13–15 weeks following PMX model induction. Cartilage degradation was assessed in knee joint sections stained with Safranin O and fast green in PMX mice. Antigen induced arthritis produced knee joint swelling and PMX caused degeneration of articular cartilage in the knee. In the first 46 h following AIA, mice travelled less distance and were less mobile compared to their control cage mates. In contrast, no such differences were found between PMX and sham mice when measured between 4–12 weeks post-surgery. A larger fraction of joint neurons showed spontaneous activity in AIA but not PMX mice. Spontaneous activity was mostly displayed by medium-sized neurons in AIA mice and was not correlated with any of the home cage behaviors. Group-housed home cage monitoring revealed locomotor changes in AIA mice, but not PMX mice (with n = 10/group). In vivo calcium imaging can be used to assess activity in multiple retrogradely labelled joint afferents and revealed increased spontaneous activity in AIA but not PMX mice.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"99 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort","authors":"S. Bellando-Randone, H. Wilhalme, C. Bruni, L. Czirjak, O. Distler, Y. Allanore, G. Cuomo, C. Denton, F. Del Galdo, A. M. Gheorghiu, V. Riccieri, U. Walker, M. E. Truchetet, M. C. Vonk, I. Foeldvari, M. Matucci-Cerinic, D. E. Furst","doi":"10.1186/s13075-025-03476-0","DOIUrl":"https://doi.org/10.1186/s13075-025-03476-0","url":null,"abstract":"To evaluate the use of hydroxychloroquine (HCQ) and its impact on the Health Assessment Questionnaire disability index(HAQ-DI) and the Cochin Hand Function Status(CHFS) in a large Systemic Sclerosis (SSc) cohort. SSc patients from the European Scleroderma Trials and Research (EUSTAR) database treated with HCQ for at least 6 months were evaluated and compared to a matched group of SSc patients not using HCQ. Demographic and clinical data, concomitant drugs, HAQ-DI and CHFS (at least 2 evaluations) were recorded and were the outcome variables of interest. Statistical analysis was performed using propensity score matching for age, gender, disease duration, corticosteroids, immunosuppressives, vasoactive drugs in a 3:1 control: HCQ ratio. Standard descriptive statistics and Student’s t-test and Chi-square test were used to assess the propensity-matched groups. Out of 17,805 SSc patients evaluated, 468 (2.6%) used HCQ and constituted the HCQ group. Among them, 50 (10.7%) had at least a baseline and follow-up HAQ-DI evaluation and 44 (9.4%) had at least a baseline and follow-up CHFS evaluation. Propensity matching assured that patients were matched for female gender (HCQ vs. control 92.0% vs. 85.3%), mean age (49.8 vs. 50.0 years) disease duration (8.3 vs. 9.1 years), limited disease (55.3 vs. 62.6%) as well as background medications (all P > 0.1). We did not find any significant differences among the two groups in the change of HAQ-DI or CHFS, over up to 365 days (all P > 0.05). Results from the EUSTAR registry showed that HCQ was used by 2.6% of SSc patients. HCQ use did not improve the HAQ-DI, or CHFS when comparing HCQ users to non-HCQ users.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"35 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143713083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis using machine learning: a deep learning model trained on the KURAMA cohort and externally validated with the ANSWER cohort","authors":"Takayuki Fujii, Koichi Murata, Hirohiko Kohjitani, Akira Onishi, Kosaku Murakami, Masao Tanaka, Wataru Yamamoto, Koji Nagai, Ayaka Yoshikawa, Yuki Etani, Yasutaka Okita, Naofumi Yoshida, Hideki Amuro, Tadashi Okano, Yo Ueda, Takaichi Okano, Ryota Hara, Motomu Hashimoto, Akio Morinobu, Shuichi Matsuda","doi":"10.1186/s13075-025-03541-8","DOIUrl":"https://doi.org/10.1186/s13075-025-03541-8","url":null,"abstract":"Undifferentiated arthritis (UA) often develops into rheumatoid arthritis (RA), but predicting disease progression from seronegative UA remains challenging because seronegative RA often does not meet the classification criteria. This study aims to build a machine learning (ML) model to predict the progression from seronegative UA to RA using clinical and laboratory parameters. KURAMA cohort (training dataset) and ANSWER cohort (validation dataset) were utilized. Patients with seronegative UA were selected based on specific inclusion and exclusion criteria. Clinical and laboratory parameters, including demographic data, acute phase reactants, autoantibodies, and physical examination findings, were collected. Various ML models, including a Feedforward Neural Network (FNN), were developed and compared. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), sensitivity, and other metrics. SHapley Additive exPlanations (SHAP) values were computed to interpret the importance of variables. KURAMA cohort included 210 patients with seronegative UA, of whom 57 (27.1%) progressed to RA. The FNN model demonstrated the highest predictive performance with an AUC of 0.924 and a sensitivity of 80.7% in the training dataset. Validation with ANSWER cohort (140 patients; 32.1% progressed to RA) showed an AUC of 0.777, sensitivity of 77.8%. MMP-3 had the highest impact on the model. The FNN model exhibited robust performance in predicting the progression of RA from seronegative UA and maintained substantial sensitivity in an independent validation cohort. This model using only clinical and laboratory parameters has potential for predicting RA progression in patients with seronegative UA.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"29 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143703284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: IL13Rα1 protects against rheumatoid arthritis by combating the apoptotic resistance of fibroblast-like synoviocytes","authors":"Xiaomei Yang, Qingwei Guo, Tingting Feng, Qiqi Lu, Luna Ge, Jihong Pan, Kehong Bi, Li Qiao, Lei Tian, Tianhua Xie, Chengfang Yao, Guanhua Song, Lin Wang","doi":"10.1186/s13075-025-03540-9","DOIUrl":"https://doi.org/10.1186/s13075-025-03540-9","url":null,"abstract":"<p><b>https://doi.org/10.1186/s13075-020-02270-4</b>.</p><p>Following publication of the original article [1], the authors reported an error in Fig. 5D. The images of haematoxylin-eosin (H&E) and Safranin O/Fast green staining in Fig. 5d was mistakenly used, as more than one pathological gene, besides IL13Rα1 was investigated. The corrected Fig. 5D is provided below.</p><figure><figcaption><b data-test=\"figure-caption-text\">Fig. 5</b></figcaption><picture><source srcset=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-025-03540-9/MediaObjects/13075_2025_3540_Fig4_HTML.png?as=webp\" type=\"image/webp\"/><img alt=\"figure 4\" aria-describedby=\"Fig4\" height=\"219\" loading=\"lazy\" src=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-025-03540-9/MediaObjects/13075_2025_3540_Fig4_HTML.png\" width=\"685\"/></picture><p>Incorrect Figure</p><span>Full size image</span><svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-chevron-right-small\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></figure><figure><figcaption><b data-test=\"figure-caption-text\">Fig. 5</b></figcaption><picture><source srcset=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-025-03540-9/MediaObjects/13075_2025_3540_Fig5_HTML.png?as=webp\" type=\"image/webp\"/><img alt=\"figure 5\" aria-describedby=\"Fig5\" height=\"223\" loading=\"lazy\" src=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-025-03540-9/MediaObjects/13075_2025_3540_Fig5_HTML.png\" width=\"685\"/></picture><p>Correct Figure</p><span>Full size image</span><svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-chevron-right-small\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></figure><ol data-track-component=\"outbound reference\" data-track-context=\"references section\"><li data-counter=\"1.\"><p>Yang X., Guo Q., Feng T., <i>et al</i>. IL13Rα1 protects against rheumatoid arthritis by combating the apoptotic resistance of fibroblast-like synoviocytes. Arthritis Res Ther. 2020;22:184. https://doi.org/10.1186/s13075-020-02270-4.</p></li></ol><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Department of Hematology, Qilu Children’s Hospital of Shandong University, Jinan, China</p><p>Xiaomei Yang & Qingwei Guo</p></li><li><p>Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China</p><p>Xiaomei Yang & Kehong Bi</p></li><li><p>Department of Pathology, Shandong University Medical School, Jinan, China</p><p>Tingting Feng</p></li><li><p>Department of Rheumatology and Autoimmunology, The First Affiliated Hospital of Shandong First Medical University, Key Lab for Biotech-Drugs of National Health Commissi","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"16 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143695101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease","authors":"Oliver Distler, Madelon C Vonk, Arata Azuma, Maureen D. Mayes, Dinesh Khanna, Kristin B. Highland, Gerrit Toenges, Margarida Alves, Yannick Allanore","doi":"10.1186/s13075-025-03524-9","DOIUrl":"https://doi.org/10.1186/s13075-025-03524-9","url":null,"abstract":"We used data from the SENSCIS and SENSCIS-ON trials to assess decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who received long-term treatment with nintedanib and the effect of switching patients from placebo to nintedanib. In the SENSCIS trial, patients were randomised to receive nintedanib or placebo until the last patient reached week 52 but for ≤ 100 weeks. In SENSCIS-ON, the extension to SENSCIS, all patients received open-label nintedanib. Per protocol, the off-treatment period between these trials was ≤ 12 weeks. We assessed the trajectory of FVC in patients who received nintedanib in SENSCIS and continued nintedanib in SENSCIS-ON (n = 197) and in patients who received placebo in SENSCIS and initiated nintedanib in SENSCIS-ON (n = 231). The last on-treatment measurement in SENSCIS and the baseline measurement of SENSCIS-ON were considered anchor measurements. In patients who received nintedanib in SENSCIS, the mean decline in FVC in the 52 weeks prior to the last on-treatment measurement in SENSCIS was − 41.5 mL and the mean decline in FVC from baseline to week 52 of SENSCIS-ON was − 58.3 mL. In patients who received placebo in SENSCIS, the mean decline in FVC in the 52 weeks prior to the last on-treatment measurement in SENSCIS was − 96.8 mL and the mean decline in FVC from baseline to week 52 of SENSCIS-ON (when patients received nintedanib) was − 42.8 mL. These findings illustrate the progressive nature of SSc-ILD and support the efficacy of nintedanib in slowing decline in lung function over the long term.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"93 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143666224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nailfold videocapillaroscopy findings are associated with IIM subtypes and IFN activation","authors":"Mingwei Tang, Jia Shi, Yiyun Pang, Shuang Zhou, Jinjing Liu, Chanyuan Wu, Mengtao Li, Xiaofeng Zeng, Qian Wang","doi":"10.1186/s13075-025-03532-9","DOIUrl":"https://doi.org/10.1186/s13075-025-03532-9","url":null,"abstract":"This study aimed to characterize nailfold videocapillaroscopy (NVC) features in patients with different subtypes of Idiopathic inflammatory myopathy (IIM) and to investigate the correlations between NVC findings, myositis-specific antibody (MSA) subtypes, disease activity, cytokine profiles, and interferon-stimulated gene (ISG) expression levels. This cross-sectional observational single-center study included 55 IIM patients, categorized into MDA5 (+), anti-aminoacyl-tRNA-synthetase antibodies (ARS) (+), and MSA(-) groups based on their MSA profiles. Demographic data, laboratory tests, and NVC assessments were systematically collected and analyzed. The relative expression of type I ISGs in whole blood, as well as serum cytokine and chemokine profiles, were measured. Statistical analyses were performed to explore correlations between NVC scores and clinical parameters, including serum biomarkers. NVC abnormalities were observed in most IIM patients, with significant differences in NVC features among the MSA subgroups. The MDA5(+) group exhibited significantly higher scores for capillary dilation (P < 0.01), giant capillaries (P < 0.05), microhemorrhages (P < 0.01), and abnormal capillary morphology (P < 0.05) compared to the ARS (+) group. ISG expression and cytokine levels were upregulated in IIM patients, with active disease patients showing significantly higher levels of certain ISGs and cytokines compared to clinically stable patients. Notably, specific NVC score dimensions were positively correlated with the levels of certain ISGs and cytokines. For example, microhemorrhage, capillary dilation, and capillary density all had significantly positive correlations with MX1, IFI27, IP-10, RANTES, and GROα (P < 0.05). And giant capillary is also related to levels of IFI27, SDF-1α, IP-10, RANTES, and GROα (P < 0.05). IIM patients exhibit distinct NVC abnormalities, which vary across different MSA subtypes. NVC findings have potential clinical value in screening disease activity and interferon pathway activation in IIM patients.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"59 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143661190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Course of uveitis in children with juvenile idiopathic arthritis (JIA): Five years follow-up data from a prospective multicenter Inception Cohort of Newly diagnosed patients with JIA (ICON-JIA) study","authors":"Karoline Baquet-Walscheid, Kirsten Minden, Martina Niewerth, Frank Dressler, Ivan Foeldvari, Dirk Foell, Johannes-Peter Haas, Gerd Horneff, Anton Hospach, Tilmann Kallinich, Jasmin Kümmerle-Deschner, Kirsten Mönkemöller, Christoph Tappeiner, Daniel Windschall, Jens Klotsche, Arnd Heiligenhaus","doi":"10.1186/s13075-025-03531-w","DOIUrl":"https://doi.org/10.1186/s13075-025-03531-w","url":null,"abstract":"Juvenile idiopathic arthritis-associated uveitis (JIAU) typically takes a chronic course, frequently leading to ocular complications and often requiring long-term treatment. The present study assesses the 5-years outcome of JIAU by analyzing data from a prospective study initiated in 2010. Data from 75 patients with onset of uveitis after study enrollment, and with a documentation at 5-years follow-up (5yFU) were available for analysis of uveitis characteristics, frequency and predictors of „inactivity on medication “ (defined as inactive uveitis for ≥ 6 months) and „inactivity off medication “ (defined as inactive uveitis for ≥ 6 months off medication). At the 5yFU, visual acuity remained good in the majority of eyes (LogMAR < 0.1 in 65.5%; mean LogMAR 0.11 ± 0.31), ocular surgery was required in only 5% of patients, although complications occurred in 46.7% of patients until the 5yFU. Uveitis was inactive in 85.3% of patients, with 77.3% still receiving disease-modifying antirheumatic drugs (DMARDs). Until 5yFU, 82.7% of patients experienced ≥ one episode of „inactivity on medication “ (30.7% once, 37.3% twice, 14.7% three or more times), and 17.3% ≥ one episode of „inactivity off medication “, respectively. Both „inactivity on medication “ as well as „inactivity off medication “ were associated with lower JIA disease activity (cJADAS10; ESR), and with an increased quality of life. Despite intensified DMARD treatment, almost half of the children experience JIAU-related ocular complications after 5 years of disease; however, visual acuity mostly remains good. Uveitis inactivity can be achieved frequently, but is often limited in duration. Lower JIA activity appears to correlate with uveitis inactivity on and off medication.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"92 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143661200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}